JP7813234B2 - 抗ｔｍｐｒｓｓ６抗体及びその用途 - Google Patents

抗ｔｍｐｒｓｓ６抗体及びその用途

Info

Publication number
JP7813234B2
JP7813234B2 JP2022548950A JP2022548950A JP7813234B2 JP 7813234 B2 JP7813234 B2 JP 7813234B2 JP 2022548950 A JP2022548950 A JP 2022548950A JP 2022548950 A JP2022548950 A JP 2022548950A JP 7813234 B2 JP7813234 B2 JP 7813234B2
Authority
JP
Japan
Prior art keywords
tmprss6
antibody
seq
mwtx
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022548950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520969A (ja
JP2023520969A5 (OSRAM
Inventor
デュー，シン
チェン，バクシン
ジン ワン，ユ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mabwell Therapeutics Inc
Original Assignee
Mabwell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabwell Therapeutics Inc filed Critical Mabwell Therapeutics Inc
Publication of JP2023520969A publication Critical patent/JP2023520969A/ja
Publication of JP2023520969A5 publication Critical patent/JP2023520969A5/ja
Application granted granted Critical
Publication of JP7813234B2 publication Critical patent/JP7813234B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022548950A 2020-04-07 2021-04-05 抗ｔｍｐｒｓｓ６抗体及びその用途 Active JP7813234B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063006695P 2020-04-07 2020-04-07
US63/006,695 2020-04-07
US202163158265P 2021-03-08 2021-03-08
US63/158,265 2021-03-08
PCT/US2021/025775 WO2021207072A1 (en) 2020-04-07 2021-04-05 Anti-tmprss6 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023520969A JP2023520969A (ja) 2023-05-23
JP2023520969A5 JP2023520969A5 (OSRAM) 2024-04-26
JP7813234B2 true JP7813234B2 (ja) 2026-02-12

Family

ID=75888147

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548950A Active JP7813234B2 (ja) 2020-04-07 2021-04-05 抗ｔｍｐｒｓｓ６抗体及びその用途

Country Status (9)

Country Link
US (3) US12215170B2 (OSRAM)
EP (1) EP4126220A1 (OSRAM)
JP (1) JP7813234B2 (OSRAM)
KR (1) KR20230007368A (OSRAM)
CN (1) CN115243762A (OSRAM)
AU (1) AU2021251087A1 (OSRAM)
CA (1) CA3174339A1 (OSRAM)
TW (1) TW202204422A (OSRAM)
WO (1) WO2021207072A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230295345A1 (en) * 2020-04-07 2023-09-21 Mabwell Therapeutics, Inc. Anti-tmprss6 antibodies and uses thereof
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
AU2022274888A1 (en) * 2021-05-11 2023-12-07 Regeneron Pharmaceuticals, Inc. Anti-tmprss6 antibodies and uses thereof
CN120752046A (zh) * 2022-11-25 2025-10-03 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
EP4688867A2 (en) * 2023-04-04 2026-02-11 Disc Medicine, Inc. Anti-tmprss6 antibodies and uses thereof
AU2024243972A1 (en) * 2023-04-06 2025-10-23 Memorial Hospital For Cancer And Allied Diseases Il-10 receptor antibodies and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
WO2008009895A2 (en) 2006-07-18 2008-01-24 University College Cardiff Consultants Limited Matriptase-2
JP2017502030A (ja) 2013-12-17 2017-01-19 カイマブ・リミテッド 対象とするヒト標的に特異的に結合するリガンド
JP2018529756A (ja) 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
AR065083A1 (es) * 2007-02-02 2009-05-13 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
WO2013070786A1 (en) * 2011-11-07 2013-05-16 Isis Pharmaceuticals, Inc. Modulation of tmprss6 expression
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
WO2016071701A1 (en) * 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
CA3162880A1 (en) 2019-11-29 2021-06-03 Kymab Limited Treatment for physiological iron overload
AU2021251087A1 (en) 2020-04-07 2022-12-01 Mabwell Therapeutics Inc. Anti-TMPRSS6 antibodies and uses thereof
BR112023022284A2 (pt) 2021-04-26 2023-12-26 Alnylam Pharmaceuticals Inc Composições de irna de protease transmembrana, serina 6 (tmprss6) e métodos de uso da mesma
AU2022265493A1 (en) 2021-04-27 2023-09-21 Silence Therapeutics Gmbh Sirna targeting tmprss6 for the treatment of myeloproliferative disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054027A1 (en) 2003-09-09 2005-03-10 Irm Llc Modulators of transmembrane protease serine 6
WO2008009895A2 (en) 2006-07-18 2008-01-24 University College Cardiff Consultants Limited Matriptase-2
JP2017502030A (ja) 2013-12-17 2017-01-19 カイマブ・リミテッド 対象とするヒト標的に特異的に結合するリガンド
JP2018529756A (ja) 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Blood，2019年11月13日，134 (Supplement_1) : 3532，pp.1-2
Chinese Journal of Hemorheology，2014年，Vol.24, No.4，pp.472-475

Also Published As

Publication number Publication date
EP4126220A1 (en) 2023-02-08
JP2023520969A (ja) 2023-05-23
CA3174339A1 (en) 2021-10-14
AU2021251087A1 (en) 2022-12-01
WO2021207072A1 (en) 2021-10-14
CN115243762A (zh) 2022-10-25
US20230203196A1 (en) 2023-06-29
US20230348623A1 (en) 2023-11-02
US12215170B2 (en) 2025-02-04
KR20230007368A (ko) 2023-01-12
TW202204422A (zh) 2022-02-01
US20250304719A1 (en) 2025-10-02
US11866513B2 (en) 2024-01-09

Similar Documents

Publication Publication Date Title
US11866513B2 (en) Anti-TMPRSS6 antibodies and uses thereof
CN105392800B (zh) 抗cxcl1、cxcl7和cxcl8抗体及其应用
US20240002488A1 (en) Method of treating or preventing liver conditions
RU2744909C2 (ru) Способ лечения или предотвращения инсульта
CN111138540A (zh) 治疗自身免疫疾病的结合fcrn的抗体
AU2016218900A1 (en) Methods and compositions for modulating LILR proteins
RU2718054C2 (ru) Способ лечения нефропатии
EP3976656A1 (en) Alk7 binding proteins and uses thereof
US20230295345A1 (en) Anti-tmprss6 antibodies and uses thereof
US20200109211A1 (en) Compounds binding human cd160 and uses thereof
US20250136718A1 (en) Anti-tmprss6 antibodies and uses thereof
KR20250128393A (ko) 항-tmprss6 항체 및 그의 용도
CN118078985A (zh) 抗tmprss6抗体及其用途
HK40079278A (en) Anti-tmprss6 antibodies and uses thereof
HK40104812A (zh) 抗tmprss6抗体及其用途
RU2790023C2 (ru) Способы лечения заболевания с применением ингибиторов костного морфогенетического белка 6 (вмр6)
CN121039165A (zh) 抗tf抗体和抗tf抗体-药物偶联物及其医药用途
HK40018330A (en) Antibody binding to fcrn for treating autoimmune diseases
HK1230217A1 (en) Antibody binding to fcrn for treating autoimmune diseases

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260130

R150 Certificate of patent or registration of utility model

Ref document number: 7813234

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150